Background/Purpose: The efficacy of Golimumab (GLM) treatment in psoriatic arthritis (PsA) patients has been widely documented. The aim of this study was to analyze the long-term retention of GLM and to identify independent predictors of drug retention in patients with PsA including concomitant DMARD.

Methods: Prospective monocentric cohort of PsA patients treated with GLM according to clinical practice. Study was approved by local Ethics Committee. Demographic and clinical variables were analyzed with Cox proportional hazard regression model.

Results: 48 patients were included, 20/48 (41.7%) oligoarticular, 19/48 (39.6%) polyarticular and 9/48 (18.7%) with peripheral and axial PsA.  The baseline characteristics of the patients are shown in Table 1. Mean follow-up time was 22.3 months (SD 19.0). Mean survival time was 40.3 months (95% CI: 32.0-48.5).  Age, mean evolution time and previous biological use were significant in the univariate analysis. Concomitant DMARD had no influence on GLM retention rate (HR: 1.3; 95% CI: 0.5-3.2; p: 0.6). Figure 1. Patients with PsA treated with GLM as first or second biological tended to have a better retention rate of the drug, but did not reach statistical significance. Fig 2. 18/48 (37.5%) withdraw GLM treatment. 13/18 (72.2%) due to lack of efficacy, 1/18 (0.6%) due to adverse events and 4/18 (22.2%) due to other reasons.

Table 1. Baseline demographic and clinical characteristics of the patients.

Conclusion: Real-world Golimumab retention rate in patients with PsA was good and did not depend on concomitant treatment with DMARD.  When used as first or second biologic, Golimumab retention rate tend to be better.